Report from Annual General Meeting in Vigmed Holding

On May 13, 2015, Vigmed Holding AB (publ) held its Annual General Meeting. At
the AGM, 17, 742, 318 shares were represented, 41 % of all shares. A summary of
the resolutions follows below. All resolutions were passed with the required
majority.
The AGM resolved to adopt the presented Income Statement and Balance Sheet, and
the Consolidated Income Statement and Consolidated Balance Sheet. The Meeting
also resolved to appropriate the Company’s profit or loss in accordance with the
Board of Directors’ proposal in the Annual Accounts. Additionally, the Meeting
resolved that no dividend is paid for the financial year 2014.

The AGM resolved to discharge the Board members and Chief Executive Officer from
liability.

The AGM resolved that the Board of Directors will consist of Lennart Holm, Per
Knutsson, Rikard Roos, Mikael Karlsson, Lennart Dreyer, Thomas Baier, Axel
Sjöblad and Philip Nyblaeus.  Lennart Holm was re-elected as Chairman of the
Board. The remuneration shall be SEK 150,000 to the Chairman and SEK 85,000 to
every Board member who is not employed by the company.

The AGM also resolved that, as in the previous year, auditors’ fees are payable
in accordance with approved account, on the customary debiting terms. It was
resolved that AB Öhrlings PricewaterhouseCoopers continue as the Company’s
auditor and that responsible accountant is Christer Kilefors.

The Annual General Meeting decided to grant the Board of Directors
authorization, to decide on new share issue, on one or more occasions during the
period until the next AGM, with or without waiving shareholders preferential
rights. Issues may be made with or without the provision of contribution, set
-off or other terms. The number of shares to be issued may not exceed a total of
10,958,333. Dilution of capital may, upon full exercise of the authorization,
amount to no more than about 20 percent of the registered share capital at the
time of the Annual General Meeting. The intention of the authorization is to
enable the raise of working capital, to finance expansion of the sales and
marketing organization and to initiate the development of new product lines. To
the extent the authorization is used for issue against cash payment waiving the
shareholders’ preferential rights, the issue price should be market-based. The
resolution was made in accordance with the proposal, see item 15, in the notice
to the AGM published 13 April 2015.

Helsingborg, May 15 2015

Vigmed Holding AB
For further information contact:

Chairman of the board, Lennart Holm +46 70 630 8562
Vigmed is a Swedish medical technology company whose mission is to eliminate
needlestick injuries and the associated risk of cross infections with blood
-borne infectious diseases by offering the market unique needle-protected
products. Vigmed is headquartered in Helsingborg, Sweden, and has 20 employees.
Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and
has approximately 5 600 shareholders. Remium Nordic AB is the Company’s
Certified Advisor.

Additional information about the company can be found on Vigmed’s website:
www.vigmed.com/investor